Login / Signup

Efficacy of tocilizumab in highly relapsing MOGAD with an inadequate response to intravenous immunoglobulin therapy: A case series.

You-Ri KangKi Hoon KimJae-Won HyunSu-Hyun KimHo Jin Kim
Published in: Multiple sclerosis and related disorders (2024)
Targeting the IL-6 pathway appears to offer therapeutic benefits in highly relapsing MOGAD patients who poorly respond to IVIG maintenance therapy.
Keyphrases
  • multiple sclerosis
  • rheumatoid arthritis
  • disease activity
  • high dose
  • stem cells
  • juvenile idiopathic arthritis
  • cancer therapy
  • systemic lupus erythematosus
  • cell therapy
  • smoking cessation